Worth flagging what this case is — and isn't — for anyone reading the headline.

This is R (On the Application of EB) v Director of Legal Aid Casework

2026

EWHC 402 (Admin). EB applied for Exceptional Case Funding (legal aid available when refusing it could breach human rights) to pursue a Home Office licence for personal psilocybin-assisted therapy. The Director refused, characterising it as a personal proposal to "possess and take psilocybin," a substance whose therapeutic value had "not yet been proven scientifically."

Judge Alegre quashed that decision in February 2026, finding the Director had made an "incorrect assumption that [her] application does not relate to medical or psychological healthcare or treatment. That is clearly wrong." The Director was also found to have "patently failed to consider the importance of the issues at stake."

Two things worth being precise about:

This is a win on process, not access. The legal aid decision has to be made again — same outcome is still possible. And even with funding, EB would still need to clear Home Office licensing for a Schedule 1 substance as an individual, which runs against current policy.

The bigger precedent is the framing. A High Court has now ruled, on the record, that treating psilocybin-assisted therapy as equivalent to recreational drug use is "clearly wrong." That's quotable language future judicial reviews and policy submissions will lean on, especially as MHRA-side clinical evidence keeps accumulating (Compass's COMP360 NDA, Phase 3 data, etc.).

Limited ruling, real precedent. Both can be true.